Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1 + 1460 word(s) 1460 2021-06-28 08:09:02 |
2 form corrected -6 word(s) 1454 2021-07-01 06:03:17 |

Video Upload Options

Do you have a full video?


Are you sure to Delete?
If you have any further questions, please contact Encyclopedia Editorial Office.
Strookappe, B. Health-Related Quality of Life (HRQoL). Encyclopedia. Available online: (accessed on 19 April 2024).
Strookappe B. Health-Related Quality of Life (HRQoL). Encyclopedia. Available at: Accessed April 19, 2024.
Strookappe, Bert. "Health-Related Quality of Life (HRQoL)" Encyclopedia, (accessed April 19, 2024).
Strookappe, B. (2021, June 30). Health-Related Quality of Life (HRQoL). In Encyclopedia.
Strookappe, Bert. "Health-Related Quality of Life (HRQoL)." Encyclopedia. Web. 30 June, 2021.
Health-Related Quality of Life (HRQoL)

HRQoL is a multi-dimensional concept that reflects the degree to which a health condition interferes with participation in and fulfillment of important life areas. HRQoL is intended to capture the composite degree of physical, physiologic, psychological, and social impairment resulting from symptom burden, patient-perceived disease severity, and treatment side effects.

sarcoidosis quality of life symptom burden symptom distress shared decision making patient-centeredness patient centered care mindfulness exercise physical activity

1. Introduction

Sarcoidosis is a phenotypically heterogeneous, systemic disease of unknown etiology characterized pathologically by the presence of non-caseating granulomas in one or multiple organs. Though sarcoidosis potentially resides in any organ and most commonly recognized with pulmonary, cutaneous, ophthalmologic involvement; neurologic, cardiac, gastrointestinal, hepatic, and renal involvement are likely under-recognized. The presence of granulomas may be silent or cause severe or life-threatening organ dysfunction resulting in multiple and diverse symptoms that impair physical function and psycho-social realms of function due to direct effects of disease or treatment effects. Sarcoidosis-related impairments can impede routine activities of daily living (ADLs) and disrupt critical life areas: work, family, and social/leisure; and also impact psychological well-being.

When relying predominantly on positive biomarkers, radiologic, and physiologic testing to guide treatment, a patient’s physical, psychological, and cognitive impairment in sarcoidosis can often be overlooked by clinicians [1][2]. Clinician-recognition that “absence of evidence does not mean evidence of absence”, especially when PET/CT is not available, is crucial in considering patient history. It should be acknowledged that sarcoidosis patients prioritize quality of life issues over most objective clinical tests to assess their disease [1][2].

Health-related quality of life (HRQoL), though rarely a primary endpoint in clinical trials, may be the single outcome most reflective of patient priorities when living with a health condition [3]. HRQoL is a multi-dimensional concept that reflects the degree to which one’s health condition impairs the ease with which one is able to interface with crucial areas of life activity: making a living, engaging with loved ones, and pursuing life’s interests [4]. Health status, or physical function, is only one component of HRQoL, and therefore measures that are specific to health status/physical function do not measure the extent of HRQoL [5]. HRQoL reflects how important life areas are enhanced or diminished by the health condition, treatment, and environmental influences.

2. Medication-Related and Complication-Related HRQoL

Management of medication side effects, offers further opportunity to improve HRQoL. Clinician acknowledgement that, although anti-sarcoidosis medication may effectively treat sarcoidosis and thereby improve HRQoL, the side effects of medication may paradoxically worsen HRQoL. Again, if the clinician focuses solely on objective measures of physiologic improvement and lessening of granulomatous inflammation, medication side effects that impair HRQoL may go undetected.

The impact of glucocorticoids on HRQoL and adverse outcomes cannot be overstressed. While in some cases life-saving, glucocorticoids predictably create short-term intolerability and pose long-term risk of lasting detrimental harm to multiple organ systems. Long-term use of glucocorticoids has resulted in reports of multiple and diverse adverse events in sarcoidosis patients on prednisone and similar glucocorticoids [6][7][8][9][10], including severe infection, psychosis, insomnia, cataracts, glaucoma, gastrointestinal bleeding, myopathy, hormonal dysfunction, and skin and mucosal fragility [11].

One study demonstrated a significantly worse HRQoL for patients receiving even mild doses of prednisone [6]. Across >900 sarcoidosis patients from the UK, U.S., and the Netherlands, the strongest association between a reported side effect and drug use was that of weight gain associated with increased appetite among prednisone use [7]. Avascular necrosis, a source of severe pain, disability, and cause for surgery, and low bone density with a fracture, commonly complicate long-term use of glucocorticoids [12][13][14]. Discussions in the expert community favor elevated BMI, the presence of cardiovascular disease, diabetes, low bone mineral density, prior avascular necrosis, prior gastrointestinal bleeding or ulceration, and psychiatric history as relative contraindications to glucocorticoid use.

Other anti-sarcoidosis medications, if implemented and monitored appropriately, have good safety profiles. The authors employ prednisone judiciously, as dictated by disease severity, and only as a bridge to on-boarding steroid-sparing anti-sarcoidosis treatment, such as methotrexate. This is followed by vigilant proactive tapering of prednisone as the steroid-sparing treatment gains efficacy 4outline common adverse events, contraindications, and protective measures with glucocorticoid use.

More frequent visits, or checking in with patients during the initiation of medication, can intercept problems, early strategies, such as temporary dose reduction, drug holidays, dose timing, dose splitting, formulation changes, or concomitant PRN medications to improve tolerability. For example, most patients tolerate methotrexate very well; however, a few patients experience nausea or fatigue. Taking with food helps to reduce nausea symptoms, and if taken with evening meal; nausea/fatigue may not be noticeable during sleep. Splitting the methotrexate dose over two days, switching from oral to self-injection; PRN anti-emetics or modulating concomitant folic acid dosing all may help to mitigate symptoms.

Checklists, again, can help navigate patient experience and prevent complications; supplied below are preventive strategies. Regularly planned testing for medication toxicity monitoring to ensure avoidance of medication interruption and, at the same time, patient safety [15][16].Prescribe sufficient medication, only up until the time for the next toxicity screening test to avoid prolonged use of medication without toxicity check. Counseling on medication-related red flags for complications and preventive measures for each medication. Counseling on sunscreen use and sun exposure with certain DMARDs and biologic use [16].Supporting exercise as medicine and a stress reduction strategy are expanded upon below.

3. HRQoL Self-Management Strategies for Patients and Family Members

As discussed above, in regards to PEMs, patient education about the disease, medications that treat disease, and elements of the healthcare system are essential to motivating engagement, enhancing adherence, and increasing ability to detect and avert potential complications, and therefore protect HRQoL. Making connections with patient organizations, as described above, can provide sustenance to patients and family. Exposure to interventions that, if habituated to some degree into practice, enhance HRQoL through potential amelioration of disease activity, increased fitness, and physical function and enhancing psychological well-being.

Wellness interventions, such as mindfulness [17], yoga, tai chi, and physical activity can help fortify a patient’s ability to cope more easefully with psychological, physical and with logistical healthcare burdens [18][19][20]. The myogenic influence, discussed below inSection 7.2., and other activities that reduce the stress response, induce diffuse physiologic activity, of which vagus nerve stimulation and conditioning is an important component that sets in motion multi-faceted mechanisms within cardiopulmonary, immune system, brain, and central nervous system, and cultivated gastrointestinal responses. As an example, with reduced stress response, the myocardium relaxes in response to parasympathetic drive, with heart rate slowing that, over time, leads to strengthening heart rate variability. While chronic stress shortens chromosomal telomeres associated malignancy, autoimmunity and fibrosis, integrative interventions halt and appear to increase telomere length [21][22].

Exercise cultivates a fitness that can offset cardiopulmonary deficiency, thus facilitating greater ease, capacity and reserve for patients to interface with life experience and activities. Thus, a critical component to HRQoL is the clinician supporting, or enlisting other care team members, in safe exercise as a central part of sarcoidosis care. The focus of counseling is promoting muscular and cardiopulmonary fitness, stimulating disease-modifying mechanisms of exercise, and increasing physical activity and physical capacity. Clinician-initiated discussions on obesity are unlikely to help the patient feel connected with the important message of fitness [23].

Aerobic and muscle-strengthening exercise is recognized across healthy populations and health conditions to significantly improve HRQoL as well as cardiovascular, endothelial, metabolic/glandular, muscle structure and function, lung mechanics, mobility and systemic inflammation, fatigue and depressive symptoms, with overall beneficial effect on a wide spectrum of physiological and psychological attributes. Pulmonary rehabilitation is a feasible, safe, and effective [24][25] strategy for improving breathing, exercise tolerance, fatigue, and cough through education, regardless of underlying diagnosis (e.g., ILD, PH). Exercise safety and safety parameters in sarcoidosis-related cardiopulmonary involvement [25][26] and programmatic considerations, and enhancements in this population[27].

Evidence for the role of physical training in sarcoidosis is limited, but promising, and includes improved exercise capacity [28][29][30], muscle strength [28], and HRQoL [30], and decreased fatigue after a 12-week outpatient physical training intervention. Enduring effects on exercise capacity (VO2max and 6MWD) and HRQoL as measured by the St. George’s Respiratory Questionnaire (SGRQ) were maintained at a 6-month follow-up [30].

Exercise being a practiced coordination of movement with breath, increases skilled capacity for complex, weighty, or effort intense activities. Diaphragmatic strengthening, a consequence of many forms of exercise, is another example of exercise’s ability to fortify respiratory dynamics and to improve attributes that support respiratory capacity, e.g., balance, core strength and lower back health [31]. A large muscle, the diaphragm, potentially supports amplification of healthful myogenic pathways related to inflammation, fibrosis, mental health and cardiovascular health. Thus diaphragmatic multi-impact health strategies are increasingly being studied in inflammatory and cardiopulmonary conditions, such as singing for lung health [32][33][34], yogic breathing, tai chi [18][19][20][35], as well as some yoga and dance techniques [36].


  1. Baughman, R.P.; Barriuso, R.; Beyer, K.; Boyd, J.; Hochreiter, J.; Knoet, C.; Martone, F.; Quadder, B.; Richardson, J.; Spitzer, G.; et al. Sarcoidosis: Patient Treatment Priorities. ERJ Open Res. 2018, 4, 00141–02018.
  2. Drent, M.; Lower, E.E.; De Vries, J. Sarcoidosis-Associated Fatigue. Eur. Respir. J. 2012, 40, 255–263.
  3. Saketkoo, L.A.; Mittoo, S.; Huscher, D.; Khanna, D.; Dellaripa, P.F.; Distler, O.; Flaherty, K.R.; Frankel, S.; Oddis, C.V.; Denton, C.P.; et al. Connective Tissue Disease Related Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis: Provisional Core Sets of Domains and Instruments for Use in Clinical Trials. Thorax 2014, 69, 436–444.
  4. Drent, M.; Strookappe, B.; Hoitsma, E.; De Vries, J. Consequences of Sarcoidosis. Clin. Chest Med. 2015, 36, 727–737.
  5. De Vries, J.; Lower, E.; Drent, M. Quality of Life in Sarcoidosis: Assessment and Management. Semin. Respir. Crit. Care Med. 2010, 31, 485–493.
  6. Judson, M.A.; Chaudhry, H.; Louis, A.; Lee, K.; Yucel, R. The Effect of Corticosteroids on Quality of Life in a Sarcoidosis Clinic: The Results of a Propensity Analysis. Respir. Med. 2015, 109, 526–531.
  7. Drent, M.; Proesmans, V.L.J.; Elfferich, M.D.P.; Jessurun, N.T.; de Jong, S.M.G.; Ebner, N.M.; Lewis, E.D.O.; Bast, A. Ranking Self-Reported Gastrointestinal Side Effects of Pharmacotherapy in Sarcoidosis. Lung 2020, 198, 395–403.
  8. Baughman, R.P.; Iannuzzi, M.C.; Lower, E.E.; Moller, D.R.; Balkissoon, R.C.; Winget, D.B.; Judson, M.A. Use of Fluticasone in Acute Symptomatic Pulmonary Sarcoidosis. Sarcoidosis Vasc. Diffus. Lung Dis. Off. J. WASOG 2002, 19, 198–204.
  9. Khan, N.A.; Donatelli, C.V.; Tonelli, A.R.; Wiesen, J.; Ribeiro Neto, M.L.; Sahoo, D.; Culver, D.A. Toxicity Risk from Glucocorticoids in Sarcoidosis Patients. Respir. Med. 2017, 132, 9–14.
  10. Proesmans, V.L.J.; Drent, M.; Elfferich, M.D.P.; Wijnen, P.A.H.M.; Jessurun, N.T.; Bast, A. Self-Reported Gastrointestinal Side Effects of Antifibrotic Drugs in Dutch Idiopathic Pulmonary Fibrosis Patients. Lung 2019, 197, 551–558.
  11. Goldman, C.; Judson, M.A. Corticosteroid Refractory Sarcoidosis. Respir. Med. 2020, 171, 106081.
  12. Sharp, M.; Eakin, M.N.; Drent, M. Socioeconomic Determinants and Disparities in Sarcoidosis. Curr. Opin. Pulm. Med. 2020, 26, 568–573.
  13. Hena, K.M. Sarcoidosis Epidemiology: Race Matters. Front. Immunol. 2020, 11, 537382.
  14. Harper, L.J.; Gerke, A.K.; Wang, X.-F.; Ribeiro Neto, M.L.; Baughman, R.P.; Beyer, K.; Drent, M.; Judson, M.A.; Maier, L.A.; Serchuck, L.; et al. Income and Other Contributors to Poor Outcomes in U.S. Patients with Sarcoidosis. Am. J. Respir. Crit. Care Med. 2020, 201, 955–964.
  15. Saketkoo, L.A.; Jensen, K.; Nikoletou, D.; Newton, J.J.; Rivera, F.J.; Howie, M.; Reese, R.K.; Goodman, M.; Hart, P.B.; Bembry, W.; et al. Sarcoidosis Illuminations on Living During COVID-19: Patient Experiences of Diagnosis, Management and Survival Before and During the Pandemic. 2021; under review.
  16. Buckley, L.; Guyatt, G.; Fink, H.A.; Cannon, M.; Grossman, J.; Hansen, K.E.; Humphrey, M.B.; Lane, N.E.; Magrey, M.; Miller, M.; et al. 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis Rheumatol. 2017, 69, 1521–1537.
  17. Saketkoo, L.A.; Karpinski, A.; Young, J.; Adell, R.; Walker, M.; Hennebury, T.; Wickremasinghe, M.; Russell, A.-M. Feasibility, Utility and Symptom Impact of Modified Mindfulness Training in Sarcoidosis. ERJ Open Res. 2018, 4, 00085–02017.
  18. Tavee, J. The Last Day of Suffering: Five Steps to Health and Happiness. 2011. Available online: (accessed on 7 June 2021).
  19. Tavee, J. Bloom: Stories to Heal the Mind. 2015. Available online: (accessed on 7 June 2021).
  20. Tavee, J. The Regret Vaccine: Stories for a Healthy Mind and a Happy Life. 2020. Available online: (accessed on 7 June 2021).
  21. Duckworth, A.; Gibbons, M.A.; Allen, R.J.; Almond, H.; Beaumont, R.N.; Wood, A.R.; Lunnon, K.; Lindsay, M.A.; Wain, L.V.; Tyrrell, J.; et al. Telomere Length and Risk of Idiopathic Pulmonary Fibrosis and Chronic Obstructive Pulmonary Disease: A Mendelian Randomisation Study. Lancet Respir. Med. 2021, 9, 285–294.
  22. Arsenis, N.C.; You, T.; Ogawa, E.F.; Tinsley, G.M.; Zuo, L. Physical Activity and Telomere Length: Impact of Aging and Potential Mechanisms of Action. Oncotarget 2017, 8, 45008–45019.
  23. Sole-Smith, V. In Obesity Research, Fatphobia Is Always the X Factor. Sci. Am. 2021. Available online: (accessed on 3 June 2021).
  24. Tonelli, R.; Cocconcelli, E.; Lanini, B.; Romagnoli, I.; Florini, F.; Castaniere, I.; Andrisani, D.; Cerri, S.; Luppi, F.; Fantini, R.; et al. Effectiveness of Pulmonary Rehabilitation in Patients with Interstitial Lung Disease of Different Etiology: A Multicenter Prospective Study. BMC Pulm. Med. 2017, 17, 130.
  25. Grünig, E.; MacKenzie, A.; Peacock, A.J.; Eichstaedt, C.A.; Benjamin, N.; Nechwatal, R.; Ulrich, S.; Saxer, S.; Bussotti, M.; Sommaruga, M.; et al. Standardized Exercise Training Is Feasible, Safe, and Effective in Pulmonary Arterial and Chronic Thromboembolic Pulmonary Hypertension: Results from a Large European Multicentre Randomized Controlled Trial. Eur. Heart J. 2020.
  26. Nakazawa, A.; Cox, N.S.; Holland, A.E. Current Best Practice in Rehabilitation in Interstitial Lung Disease. Ther. Adv. Respir. Dis. 2017, 11, 115–128.
  27. Kerti, M.; Balogh, Z.; Kelemen, K.; Varga, J.T. The Relationship between Exercise Capacity and Different Functional Markers in Pulmonary Rehabilitation for COPD. Int. J. Chron. Obstr. Pulm. Dis. 2018, 13, 717–724.
  28. Strookappe, B.; Swigris, J.; De Vries, J.; Elfferich, M.; Knevel, T.; Drent, M. Benefits of Physical Training in Sarcoidosis. Lung 2015, 193, 701–708.
  29. Strookappe, B.; Elfferich, M.; Swigris, J.; Verschoof, A.; Verschakelen, J.; Knevel, T.; Drent, M. Benefits of Physical Training in Patients with Idiopathic or End-Stage Sarcoidosis-Related Pulmonary Fibrosis: A Pilot Study. Sarcoidosis Vasc. Diffus. Lung Dis. 2015, 32, 43–52.
  30. Guber, E.; Wand, O.; Epstein Shochet, G.; Romem, A.; Shitrit, D. The Short- and Long-Term Impact of Pulmonary Rehabilitation in Subjects with Sarcoidosis: A Prospective Study and Review of the Literature. Respiration 2021, 100, 1–9.
  31. Yoon, H.S.; Cha, Y.J.; You, J.; Sung, H. Effects of Dynamic Core-Postural Chain Stabilization on Diaphragm Movement, Abdominal Muscle Thickness, and Postural Control in Patients with Subacute Stroke: A Randomized Control Trial. Neurorehabilitation 2020, 46, 381–389.
  32. Lewis, A.; Cave, P.; Hopkinson, N. Singing for Lung Health: Service Evaluation of the British Lung Foundation Programme. Perspect. Public Health 2018, 138, 215–222.
  33. Kang, J.; Scholp, A.; Jiang, J.J. A Review of the Physiological Effects and Mechanisms of Singing. J. Voice Off. J. Voice Found. 2018, 32, 390–395.
  34. Idrose, A.M.; Juliana, N.; Azmani, S.; Yazit, N.A.A.; Muslim, M.S.A.; Ismail, M.; Amir, S.N. Singing Improves Oxygen Saturation in Simulated High-Altitude Environment. J. Voice 2020.
  35. Zhu, S.; Shi, K.; Yan, J.; He, Z.; Wang, Y.; Yi, Q.; Huang, H. A Modified 6-Form Tai Chi for Patients with COPD. Complement. Ther. Med. 2018, 39, 36–42.
  36. Saketkoo, L.A.; Alexanderson, H.; Lammi, M.R.; LeSage, D.; Jensen, K.; Scholand, M.B.; Volkmann, E.R.; Russell, A.-M. An Ode to the Primal Tonic of Dance—Congratulating the Life of Breath Project. Lancet Respir. Med. 2020, 8, e90–e91.
Contributor MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to :
View Times: 386
Revisions: 2 times (View History)
Update Date: 01 Jul 2021